| Adempas (riociguat) / Bayer, Merck (MSD) |
2016-000501-36: An unblinded long-term extension study in different countries and centers on orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) who received riociguat in a Bayer clinical trial |
|
|
| Not yet recruiting | 4 | 20 | Europe | Adempas 0.5 mg, Adempas 1.0 mg, Adempas 1.5 mg, Adempas 2.0 mg, Adempas 2.5 mg, BAY63-2521, Film-coated tablet, Adempas | Bayer HealthCare, BAYER AG, Bayer HealthCare | Hypertension, Pulmonary, Pulmonary arterial hypertension (PAH), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-005462-34: Study to investigate the effect of riociguat on right heart size and function in pulmonary hypertension |
|
|
| Not yet recruiting | 4 | 30 | Europe | Riociguat, MK-4836, Film-coated tablet | Thoraxklinik Heidelberg gGmbH, MSD Sharp und Dohme GmbH | Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nice Clinical Classification of Pulmonary Hypertension (PH)) or CTEPH (Group IV) with hemodynamics as stated above defined as inoperable measured at least 3 months after start of full anticoagulation or with persisting or recurrent PH after pulmonary endarterectomy at least 6 months after surgery, Patients with increased pressure and resistance of pulmonary vessels, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 30 | RoW | Riociguat (Adempas) | Chinese University of Hong Kong | Chronic Thromboembolic Pulmonary Hypertension, Balloon Pulmonary Angioplasty | 07/26 | 01/27 | | |
RIALTO, NCT02759419: A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. |
|
|
| Recruiting | 4 | 25 | Europe, RoW | Adempas (Riociguat, BAY63-2521) | Bayer | Hypertension, Pulmonary | 12/25 | 12/25 | | |
| Recruiting | 4 | 40 | Europe | Selexipag, Uptravi, oral prostacyclin IP receptor agonist (OPA), Riociguat, Adempas, soluble guanylate cyclase stimulator (sGCS), CardioMEMS pulmonary artery pressure monitor, Confirm Rx | Sheffield Teaching Hospitals NHS Foundation Trust, University of Glasgow, University of Sheffield, University of Newcastle Upon-Tyne, University of Cambridge | Pulmonary Arterial Hypertension | 01/26 | 01/26 | | |
| Recruiting | 4 | 30 | Europe | Riociguat, MK-4836, ATC code: C02KX05 | Heidelberg University, Merck Sharp & Dohme LLC | Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension | 03/26 | 03/26 | | |
| No Longer Available | 3 | | Japan, US, Canada, Europe, RoW | Adempas (Riociguat, BAY63-2521) | Bayer | Hypertension, Pulmonary | | | | |
| Active, not recruiting | 3 | 24 | Europe, Japan, RoW | Riociguat (Adempas, BAY63-2521) | Bayer, Merck Sharp & Dohme LLC | Hypertension, Pulmonary | 03/20 | 07/26 | | |
EPIPHANY, NCT05140525: Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH |
|
|
| Not yet recruiting | 3 | 15 | US | Macitentan Tablets, OPSUMIT, Riociguat, Adempas, balloon pulmonary angioplasty | Dr Sudarshan Rajagopal, Janssen Pharmaceutica N.V., Belgium | CTEPH | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 202 | Europe, Canada, Japan, US, RoW | Riociguat (Adempas, BAY63-2521), Placebo | Bayer | Hypertension, Pulmonary, Ventricular Dysfunction, Left | 06/12 | 12/25 | | |
2016-001591-30: Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil Behandling af medfødt nefrogen diabetes insipidus med riociguat eller sildenafil |
|
|
| Ongoing | 2 | 2 | Europe | Adempas, Viagra, Tablet, Adempas, Viagra | Odense University Hospital, funding | Nephrogenic diabetes insipidus because of AVP2R-mutation Diabetes insipidus på baggrund af mutation i AVP2-receptoren, Nephrogenic diabetes insipidus because of AVP2R-mutation Diabetes insipidus på baggrund af mutation i AVP2-receptoren, Diseases [C] - Hormonal diseases [C19] | | | | |
2021-001633-40: Clinical trial investigating the effect of riociguat among patients with slightly elevated blood pressure in lung vessels Klinsiche Studie über die Wirkung von Riociguat bei Patienten mit Lungenhochdruck im frühen Stadium |
|
|
| Not yet recruiting | 2 | 70 | Europe | Riociguat, MK-4836, Film-coated tablet | Thoraxklinik Heidelberg gGmbH, MSD Sharp & Dohme GmbH | early pulmonary vascular disease, defined as either a) mean pulmonary arterial pressure (mPAP) ≥25 mmHg with pulmonary vascular resistance (PVR) ≥2 to <3 WU and pulmonary arterial wedge pressure (PAWP) ≤15 mmHg or b) mPAP 21-<25 mmHg with PVR ≥2 WU, and PAWP ≤15 mmHg associated with connective tissue disease (CTD) or as idiopathic/heritable form., Early-stage disease impairing the blood flow between the heart and lungs, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 2 | 72 | Japan | Riociguat Oral Tablet | National Hospital Organization Okayama Medical Center, Bayer Yakuhin, Ltd. | Hypertension, Pulmonary | 09/23 | 01/25 | | |
| Recruiting | 2 | 28 | Europe | Riociguat, Adempas, Propylthiouracil, Propycil, Perphenazine, Perphenazin neuraxpharm | Maastricht University | Ischemic Stroke, Acute | 02/24 | 04/24 | | |
NCT03409588: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty |
|
|
| Recruiting | 2 | 20 | US | Adempas, Riociguat | University of Colorado, Denver, Bayer | Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery | 12/24 | 12/24 | | |
NCT00694850 / 2007-003928-37: Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH) |
|
|
| Active, not recruiting | 2 | 22 | Europe | Riociguat (Adempas, BAY63-2521) | Bayer | Hypertension, Pulmonary | 10/25 | 10/25 | | |
ESRA, NCT05339087: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH |
|
|
| Recruiting | 2 | 70 | Europe | Riociguat Oral Tablet, MK-4836, ATC Code: C02KX05, Placebo | Heidelberg University, Merck Sharp & Dohme LLC | Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue | 10/25 | 06/26 | | |
NCT06180096: Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets |
|
|
| Completed | 1 | 36 | RoW | Riociguat film coated tablets, Adempas Filmtabletten | Humanis Saglık Anonim Sirketi | Pulmonary Arterial Hypertension | 03/23 | 04/23 | | |
NCT03074539: Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension |
|
|
| Completed | N/A | 50 | Europe | Riociguat, Adempas, Pulmonary Endarteriectomy, PEA, Ballon Pulmonary Angioplasty, BPA | Medical University of Vienna | Chronic Thromboembolic Pulmonary Hypertension, Sleep Disordered Breathing | 12/22 | 12/22 | | |
JPMS-CTEPH, NCT02117791: Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) |
|
|
| Completed | N/A | 1298 | Japan | Riociguat (ADEMPAS, BAY63-2521) | Bayer | Hypertension, Pulmonary | 04/23 | 09/23 | | |
JPMS-PAH, NCT02428985: Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) |
|
|
| Completed | N/A | 882 | Japan | Riociguat (ADEMPAS, BAY63-2521) | Bayer | Hypertension, Pulmonary | 04/23 | 09/23 | | |
PRACTICE study, ChiCTR2000032403: Efficacy and safety of refined balloon pulmonary angioplasty combined with riociguat in the treatment of inoperable chronic thromboembolic pulmonary hypertension: a single center, open label, prospective, optimal, randomized, parallel controlled clinical study |
|
|
| Not yet recruiting | N/A | 60 | | Riociguat ;Riociguat and BPA | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, clinical project of Shanghai Pulmonary Hospital | chronic thromboembolic pulmonary hypertension | | | | |
NCT05582811: Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers |
|
|
| Completed | N/A | 15 | Europe | Dose Riociguat 2,5 or 5mg, Riociguat, Placebo | Danish Headache Center | Headache | 06/23 | 06/23 | | |
NCT05750446: Effect of Riocigaut on Migraine Attack Induction in People With Migraine |
|
|
| Completed | N/A | 22 | Europe | Riociguat (BAY 63-2521), Adempas, Placebo | Danish Headache Center | Migraine Without Aura | 02/24 | 02/24 | | |
ROAR, NCT04813926: A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) |
|
|
| Active, not recruiting | N/A | 500 | US | Riociguat (Adempas, BAY63-2521) | Bayer, Xcenda, LLC | Pulmonary Arterial Hypertension | 07/25 | 07/25 | | |
| TOP-V122 / Topadur Pharma |
| No trials found |
